The Macromolecules Division possesses an innovative drug development platform based on both eukaryotic expression and prokaryotic expression systems. Di-Kine bimolecular platform and LaMbs long-acting double-antibody platform are two eukaryotic expression platforms owned by the Macromolecules Division. In addition, the Division also possesses multiple biologics R&D platforms based on prokaryotic expression systems, including oral polypeptide platform, long-acting polypeptide platform and nano antibody technology platform.

The Di-Kine platform uses the unique Fc fusion protein dimer technology to significantly extend the circulating half-life of drugs in the body. This platform is especially suitable for the development of long-acting products of endogenous cytokines, hormones, etc. The products developed are closer to the folding and modification of its endogenous counterpart, and have better efficacy and safety. Phase III clinical studies for the innovative drug product F-627 developed based on this platform has been completed in China, Europe and the U.S., and marketing applications have been filed in the three places.

On the basis of the unique double-antibody design technology, the LaMbs long-acting double-antibody platform has great development flexibility and is suitable for the development of multi-target double-antibody products. This platform will be mainly used in product development for non-tumor indications. Products developed based on this platform are currently in the preclinical stage.

By locating a reasonable delivery site and designing a drug release system, the oral polypeptide platform can reduce the degradation by gastrointestinal enzymes and promote drug absorption, thereby making oral administration of such drugs possible, avoiding discomfort of patients caused by injection administration, and increasing compliance with drug administration.

On the basis of fatty chain modification and fusion protein technology, the long-acting polypeptide platform can enhance the combination with human serum albumin, and prolong the half-life of polypeptide drugs, thereby realizing long interval administration of polypeptide drugs.

Taking advantage of small molecular weight, good tissue permeability and flexible molecular assembly design of nano antibodies, the nano antibody platform is used for the development of antibody preparations for respiratory system and external use, as well as bi-specific and multi-specific antibody products.

At present, the Macromolecules Division has filed more than ten PCT applications related to new products on the basis of the innovative drug development platform.